Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered".

Mallet, Vincent

Mallet, Vincent.

Mallet V; Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Hepatology Service, Paris, France. Electronic address: vincent.mallet@aphp.fr.

J Hepatol ; 75(4): 990-992, 2021 10.

Article in English | MEDLINE | ID: covidwho-1318894

Subject(s)

Bile Duct Diseases; COVID-19; Ketamine; Humans; Ketamine/adverse effects; Liver Function Tests; SARS-CoV-2

Keywords

COVID-19; Chemical and Drug Induced Liver Injury; Cholangiopathy; Cholangitis; Cholestasis; Intrahepatic; Ketamine

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bile Duct Diseases / COVID-19 / Ketamine Limits: Humans Language: English Journal: J Hepatol Journal subject: Gastroenterology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google